Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new products to address cancer, recently announced that it will be hosting a Key Opinion Leader breakfast focused specifically on the treatment landscape for myelodysplastic syndromes (MDS) that will feature a prominent MD Anderson Researcher. The discussion will also include a presentation on rigosertib, the Company’s late-stage drug candidate that is capable of inhibiting cellular signaling.
MDS is a heterogeneous set of bone marrow disorders that are characterized by ineffective hematopoiesis and higher risk of developing acute myeloid leukemia (AML). The event and live webcast will happen Tuesday, June 30 between 8 and 9:30 AM in New York City.
The meeting will include presentations by Guillermo Garcia-Manero who is Deputy Chair of Translational Research, the Chief of the Section of Myelodysplastic Syndromes, Co-Director of the DNA Methylation Core, and Professor at the University of Texas MD Anderson Cancer Center; as well as Lewis R. Silverman, Professor at the Icahn School of Medicine at Mount Sinai. In addition, the Onconova management team will be providing an overview of the firms’s clinical advancement work with rigosertib, including a discussion about the design of a Phase 3 trial in those with higher-risk myelodysplastic syndromes (HR-MDS) and about the ongoing Phase 2 trials using a therapy with both azacitidine and rigosertib.
Manero is the Chief of the Section of Myelodysplastic Syndromes, Deputy Chair of Translational Research, Co-Director of the DNA Methylation Core, and Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. He is a faculty member of The University of Texas Graduate School of Biomedical Sciences at Houston and served in the past as Co-Chair of the MDS Clinical Research Consortium. He is committed to improving the outcomes for those with MDS.
Lewis Silverman is an Associate Professor of Medicine in Hematology and Medical Oncology and Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai (ISMMS). He is the leader of the Myelodysplastic Syndrome and Myeloproliferative Disease Program at ISMMS, where he was the Principal Investigator for multiple national trials for those with MDS. He played a crucial role to finish the AZA-001 trial, which resulted in the approval of the 1st drug to address MDS, azacitidine (VIDAZA®).
A team led by researchers at University of Texas MD Anderson Cancer Center recently revealed new insights on the link between dysfunctions in telomeres and myelodysplastic syndromes (MDS). The study was published in the journal Cancer Cell and is entitled “Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome.” MDS refers to a group of blood cell disorders in which the bone marrow is unable to produce mature healthy blood cells. It mainly affects elderly individuals (60 years and older) and is characterized by low levels of red blood cells (anemia), white blood cells (neutropenia) or platelets (thrombocytopenia). The blood cells produced in MDS are dysfunctional due to dysplasia, an abnormal cell shape or morphology. Patients with MDS may also experience spontaneous bleeding, easy bruising, shortness of breath, fatigue and infections.